Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.

Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res. 2017 Dec 15;23(24):7584-7595. doi: 10.1158/1078-0432.CCR-17-0676. Epub 2017 Oct 2.

PMID:
28972046
2.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy.

McCoull W, Bailey A, Barton P, Birch AM, Brown AJ, Butler HS, Boyd S, Butlin RJ, Chappell B, Clarkson P, Collins S, Davies RM, Ertan A, Hammond CD, Holmes JL, Lenaghan C, Midha A, Morentin-Gutierrez P, Moore JE, Raubo P, Robb G.

J Med Chem. 2017 Apr 13;60(7):3187-3197. doi: 10.1021/acs.jmedchem.7b00210. Epub 2017 Apr 4.

PMID:
28374589
3.

Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells.

Moss CE, Glass LL, Diakogiannaki E, Pais R, Lenaghan C, Smith DM, Wedin M, Bohlooly-Y M, Gribble FM, Reimann F.

Peptides. 2016 Mar;77:16-20. doi: 10.1016/j.peptides.2015.06.012. Epub 2015 Jul 2.

4.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

5.

GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans.

Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sörhede Winzell M, Hammar M, Xu X, Smith DM, Morgan NG.

Diabetologia. 2014 Jun;57(6):1182-91. doi: 10.1007/s00125-014-3213-0. Epub 2014 Mar 25.

6.

The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119.

Stone VM, Dhayal S, Smith DM, Lenaghan C, Brocklehurst KJ, Morgan NG.

Br J Pharmacol. 2012 Apr;165(8):2758-70. doi: 10.1111/j.1476-5381.2011.01755.x.

7.

11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.

Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, Laber D, Yu A, Convey G, Mayers R, Hegyi K, Sethi JK, Stewart PM, Smith DM, Tomlinson JW.

Diabetes. 2009 Nov;58(11):2506-15. doi: 10.2337/db09-0525. Epub 2009 Aug 12.

8.

Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo.

Meirhaeghe A, Crowley V, Lenaghan C, Lelliott C, Green K, Stewart A, Hart K, Schinner S, Sethi JK, Yeo G, Brand MD, Cortright RN, O'Rahilly S, Montague C, Vidal-Puig AJ.

Biochem J. 2003 Jul 1;373(Pt 1):155-65.

9.

Identification of Gln313 and Pro327 as residues critical for substrate inhibition in tyrosine hydroxylase.

Quinsey NS, Lenaghan CM, Dickson PW.

J Neurochem. 1996 Mar;66(3):908-14.

PMID:
8769848
10.

The use of spherical reconstituted high density lipoprotein for the measurement of cholesteryl ester transfer protein activity in human plasma.

Stone MA, Lenaghan C, Torr NC, Torkington T, Wood KE, Carey F.

Biochem Soc Trans. 1995 Aug;23(3):491S. No abstract available.

PMID:
8566391

Supplemental Content

Loading ...
Support Center